Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Launches the Sius™ Single-use TFF Skid

Published: Friday, February 15, 2013
Last Updated: Friday, February 15, 2013
Bookmark and Share
Sius™ TFF skid to be showcased at the disposable solutions for biomanufacturing tradeshow in Brussels on February 19-20, 2013.

Novasep has announced the launch of its Sius™ single-use tangential flow filtration (TFF) skid.

The TFF skid completes the Novasep proprietary, single-use TFF solution for pre-clinical to clinical cGMP biomanufacturing.

The new skid is the first on the market to offer a 100 per cent single-use TFF solution.

The Sius TFF skid is comprised of an automated bench top unit with a fully disposable flowpath and is extremely compact. It is capable of lab to pilot scale TFF operations.

Eliminating the risk of cross contamination, the unit widens the market for disposable TFF solutions, accommodating surface areas from 0.1 square meters to 2 square meters for microfiltration and ultrafiltration/diafiltration (UF/DF) applications.

Novasep has achieved a 73 to 80 per cent reduction in consumable price to USD 800/ square meter, by designing the TangenX® Sius Single-use TFF cassettes to be more cost effective. This compares to USD 3000/ square meter to USD 4000/ square meter for competing products.

The long term drive by the biopharmaceutical industry to reduce costs, including the costly effort of cleaning equipment and validation, makes it increasingly reliant on disposable technologies.

These offer numerous benefits over traditional reusable technologies. One of the most important of these is a time saving of 50 to 70 per cent using Sius technology over traditional reusable TFF technologies.

The Novasep Sius TFF skid’s flowpath can be combined with TangenX Sius TFF cassettes and filter plate inserts with the option of a feed bag, to provide a complete single-use TFF solution from a single supplier for pre-clinical to clinical cGMP biomanufacturing. It is also one of the only solutions to enable cGMP validated integrity tests.

“As the biopharmaceutical market continues to evolve, demand continues to rise for more cost-effective and comprehensive solutions,” said Alain Lamproye, president of Novasep’s Biopharma business unit.

Lamproye continued, “Novasep has reacted to this by concentrating on continuing to increase its product and service portfolio in the downstream processing marketplace and we will continue to do so. By launching Sius TFF Skid, Novasep now offers the first 100 per cent single-use TFF solution on the market whilst remaining very cost effective. We are also developing a larger scale Sius TFF skid to cover commercial scale applications.”

Novasep will be presenting the Sius TFF skid at the Disposable Solutions for Biomanufacturing tradeshow in Brussels on February 19-20, 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Novasep Opens Indian Subsidiary
New office will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Tuesday, December 10, 2013
Novasep’s European Custom Manufacturing Passes FDA Inspection
Two successful FDA inspections assure customers of Novasep’s strict compliance with US pharmaceutical processing standards.
Thursday, October 24, 2013
Novasep Appoints Christian Thiry as Chief Financial Officer
CFO appointment is a key milestone in Novasep’s senior management recruitment program.
Thursday, August 29, 2013
Novasep Appoints President and CEO
Novasep announces the appointment of Michel Spagnol as President and CEO of the company, effective from 25 June 2013.
Thursday, June 27, 2013
Novasep Appoints Fine Chemicals Market Director
Company strengthens its position by appointing Udo Steinhauer.
Thursday, June 06, 2013
Novasep Invests to Build World's Largest Chromatography Plant for the Pharmaceutical Industry
The investment of €30 million allows Novasep to build the largest chromatography plant for the production of a large volume commercial API’s in Mourenx, France.
Wednesday, October 10, 2012
Changes to Novasep Governance
Roger-Marc Nicoud becomes non-executive chairman of the board.
Wednesday, October 03, 2012
Novasep Announces Three Million Euro Investment
Company to boost its highly potent API manufacturing capabilities in Le Mans, France.
Friday, July 20, 2012
Novasep Strengthens its Management Team with Key Appointments
Appointment of Jean-Claude Romain as corporate quality director and Alain Lamproye as director of Novasep Bioproduction sites in Belgium.
Tuesday, April 24, 2012
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
Engineering Foe into Friend
Bose Grant awardee Jacquin Niles aims to repurpose the malaria parasite for drug delivery.
Important Regulator of Immune System Decoded
Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function.
Bacterial Superglue for Faster Vaccine Development
An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.
Enumeral, MD Anderson Enter Into Collaboration
Strategic collaboration aims to discover and develop potentially novel antibodies against specified targets for immunotherapy.
Joint venture for GlycoMar Limited and MicroA AS
Scottish biotechnology company GlycoMar and Norwegian technology company MicroA are pleased to announce their joint venture business Prasinotech Ltd. The new company is registered in Scotland.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!